Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Multi-Center Clinical Study Intensifies First Strike at High-Risk Cancer in Kids

13.06.2012
An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma – a deadly, hard-to-cure childhood cancer.

The experimental radiopharmaceutical, 131I-MIBG, has already been tested in children with relapsed and resistant neuroblastoma, with encouraging results in reducing tumor size. This has prompted doctors in a new multi-center pilot clinical trial to see if their innovative combination therapy can help improve cure rates for newly diagnosed children and young adults, according to Brian Weiss, MD, trial chair and an oncologist at the Cincinnati Children’s Hospital Medical Center.

Cure rates for neuroblastoma have plateaued at about 40 percent and new solutions are needed to improve outcomes, said Weiss, a member of the medical center’s Cancer and Blood Diseases Institute.

“Unlike some diseases, there is no single detectable biological sign of neuroblastoma, so it’s hard to catch early,” he explained. “Children with relapsed disease usually don’t survive more than a few years. We want to see if giving this more intensive treatment right after diagnosis will safely decrease the chances of the cancer coming back.”

Neuroblastoma is one of the most commonly diagnosed childhood cancers, developing in nerve cells outside the brain. The cancer is usually first diagnosed by showing up as a lump or mass in the belly, or near the spinal cord in the chest or neck. The disease can spread to bone, the liver, lymph nodes and bone marrow. In high-risk neuroblastoma, the tumor has often spread from its primary site and is harder to treat.

MIBG stands for Meta-Iodo-Benzyl-Guanidine, a synthesized form of the adrenal gland hormone and neurotransmitter adrenalin. MIBG concentrates selectively in the body’s sympathetic nervous system, which helps control glands and muscles. When attached to the radioactive isotope iodine-131, it’s known as 131I-MIBG. After being injected, 131I-MIBG targets and is taken up by nerve tumors like neuroblastoma. This exposes the cancer cells to very high doses of radiation from the iodine-131, with minimal toxicity to neighboring normal cells.

Standard treatment for neuroblastoma normally includes several rounds of chemotherapy combined with surgery and external radiation. In the current trial, a round of chemotherapy will be replaced by injection of 131I-MIBG combined with the chemotherapy drugs vincristine and irinotecan. The chemotherapy drugs will kill some of the cancer cells and, according to research, may help 131I-MIBG do a better job of eradicating tumor cells, said Weiss.

Patients receiving the treatment will also receive a transfusion of previously collected blood stem cells to boost their blood counts after being injected with the radioactive isotope.

The trial is coordinated through and sponsored by the Children’s Oncology Group (COG), an international research consortium of the National Cancer Institute (National Institutes of Health). Thirteen hospitals in the United States and Canada are currently participating in the trial, which is expected to last two years and include up to 44 newly diagnosed patients who have not received previous treatment for their neuroblastoma.

Data from the trial, considered a small pilot study, will be used to help inform larger subsequent clinical trials testing 131I-MIBG-vincristine-irinotecan therapy for neuroblastoma, according to Weiss. The pilot trial’s initial goal is determining the feasibility of newly diagnosed patients traveling from a participating home/regional medical center to participating specialized centers that will administer the 131I-MIBG part of therapy, and then back to their home center for the remainder of treatment.

Four of the 13 currently participating hospitals will administer the 131I-MIBG portion of the therapy, which requires special capabilities: Cincinnati Children’s, Children’s Hospital of Philadelphia, University of California-San Francisco School of Medicine, and C.S. Mott Children’s Hospital in Ann Arbor, Mich.

Other participating hospitals include: Phoenix Children’s Hospital, Medical University of Southern Carolina, University of Texas Southwestern Medical Center, Children’s Hospital Los Angeles, The Children’s Hospital Denver, Children’s National Medical Center, Primary Children’s Medical Center, Salt Lake City, University of Chicago, and University of Alabama, Birmingham. Two additional medical centers are expected to be added to the trial, Weiss said.

For more information, contact the Cincinnati Children’s Cancer and Blood Diseases Institute at 513-636-2799 or cancer@cchmc.org,or visit: http://clinicaltrials.gov/ct2/show/NCT01175356?term=MIBG&rank=13.

For more information about neuroblastoma therapies and research at the Cincinnati Children’s Cancer and Blood Diseases Institute, please visit: http://www.cincinnatichildrens.org/service/n/neuroblastoma/default/.

Contact Information
Nick Miller, 513-803-6035, nicholas.miller@cchmc.org

Nick Miller | EurekAlert!
Further information:
http://www.cchmc.org

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Microhotplates for a smart gas sensor

22.02.2017 | Power and Electrical Engineering

Scientists unlock ability to generate new sensory hair cells

22.02.2017 | Life Sciences

Prediction: More gas-giants will be found orbiting Sun-like stars

22.02.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>